Ultimate magazine theme for WordPress.

Chronic cough therapy, COVID-19 updates, dupilumab for kids, and more

11/01/2021

Read for 2 minutes

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact [email protected]

Back to Healio

Healio editors compiled a list of the most widely read pneumology news released in October.

Highlights from the previous month include new data on Gefapixant for refractory or unexplained chronic cough; FDA Approves Dupilumab for Children 6-11 Years of Age with Moderate to Severe Asthma; a new device that turns inhalers into smart inhalers; a study that found pulmonary dysfunction to persist for the first 6 months after being hospitalized for COVID-19; and more.

Source: Adobe Stock.

Read these and other articles below in no particular order.

Gefapixant shows long-term effectiveness in the treatment of chronic cough

A pooled analysis of the COUGH-1 and COUGH-2 studies showed the long-term efficacy of Gefapixant (Merck) twice daily in patients with refractory or unexplained chronic cough for up to 52 weeks, according to the data presented at the virtual CHEST annual meeting. Continue reading

Mortality with ECMO higher in the second wave of patients with COVID-19

Mortality from extracorporeal membrane oxygenation was higher in the second wave of patients with COVID-19 despite improvements in treatment prior to the start of ECMO, researchers reported at the CHEST annual meeting. Continue reading

FDA approves dupilumab for children 6 to 11 years of age with moderate to severe asthma

The FDA has approved dupilumab (Dupixent, Regeneron / Sanofi) as an additional maintenance therapy for children 6-11 years of age with moderate to severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Continue reading

Impact of COVID-19 Hospital Visiting Restrictions on Providers: Survey

In a new survey, ICUs reported the widespread use of video and spent more time communicating with families overall – much more time in some cases – and decreased job satisfaction and burnout symptoms as a result of visiting restrictions. Continue reading

Lefamulin a safe, effective alternative to moxifloxacin for unilobar, multilobar pneumonia

In a pooled analysis of the LEAP 1 and LEAP 2 studies, lefamulin (Xenleta, Nabriva Therapeutics) was safe and its efficacy in patients with unilobar and multilobar community-acquired bacterial pneumonia was comparable to that of moxifloxacin. Continue reading

BreatheSuite Announces FDA Approval for a Device That Turns Inhalers into Smart Inhalers

BreatheSuite announced that it has received 510 (k) approval from the FDA for its Metered-Dose Inhaler V1 device, which turns existing inhalers into smart inhalers for people with asthma and COPD, according to a company press release. Continue reading

The lung dysfunction persists for the first 6 months after being hospitalized for COVID-19

In a new study, researchers reported persistent lung dysfunction, symptoms, and decreased health-related quality of life in the first 6 months after being hospitalized for COVID-19, but gradual improvements were seen over time. Continue reading

FDA allows the marketing of new e-cigarette products, marking the first approval of its kind

The FDA announced that it has cleared the commercialization of three new tobacco products – the first set of electronic nicotine delivery systems ever to be approved by the FDA through the pre-market tobacco product approval route. Continue reading

Benefits of triple therapy regardless of age at the onset of asthma

The improvements observed with triple therapy with umeclidinium, fluticasone furoate, and vilanterol and the use of a higher dose of fluticasone furoate were consistent regardless of age at onset of asthma, according to new data from the CAPTAIN study. Continue reading

E-cigarettes with nicotine can interfere with thrombotic activity, affect microcirculation

The use of e-cigarettes that contain nicotine can lead to an immediate increase in blood clot formation and worsening of the dilation and dilation of small blood vessels, researchers reported. Continue reading

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact [email protected]

Back to Healio

Comments are closed.